Market Research Report
Europe Diabetes Drugs Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||618294|
|Published||Content info||72 Pages
Delivery time: 1-2 business days
|Europe Diabetes Drugs Market Forecast 2019-2027|
|Published: October 8, 2018||Content info: 72 Pages||
The CAGR for the European market of diabetes drugs is expected to be 5.09% for the forecast period of 2019-2027. The increase in life expectancy contributes to the increase in the number of diseases prevailing in the region, especially diabetes. Implications caused by diabetes such as CVDs, kidney failure, foot ulcers and damage to the eyes have made people in Europe more conscious about diabetes management.
The growing number of individuals with diabetes contributes to the market growth in this region. Due to the same reason, there are increased number of admissions in hospital, both in emergency and non-emergency. These cases are generally associated with factors like sedentary lifestyle and poor diet. Key growth drivers include a preference for foreign drugs rather than domestically manufactured products. Several global pharmaceutical companies have already announced plans to build factories in the European region.
Leading market players in the European market for diabetes drugs are Novo Nordisk A/S, Xoma Corp., B.Braun Melsungen Ag, Astellas Pharma, Macrogenics, Inc., Glaxosmithkline, Pfizer, Xeris Pharmaceuticals, AstraZeneca Plc., Eli Lilly And Company, Sanofi, Diavacs Inc., Albireo Pharma Inc. and Merck.